Quest Diagnostics Incorporated (QDI.F)
| Previous close | 126.45 |
| Open | 127.95 |
| Bid | 128.65 x 30000 |
| Ask | 128.80 x 30000 |
| Day's range | 127.95 - 127.95 |
| 52-week range | 113.65 - 130.10 |
| Volume | |
| Avg. volume | 5 |
| Market cap | 14.447B |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | 18.49 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.81 (2.23%) |
| Ex-dividend date | 05 Apr 2024 |
| 1y target est | N/A |
- PR Newswire
Quest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads Conference
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas on Wednesday, May 29, 2024, at 10:20 a.m. Eastern Time.
- PR Newswire
Quest Diagnostics Names Murali Balakumar Senior Vice President and Chief Information and Digital Officer
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced today that Murali Balakumar, a veteran information technology healthcare business leader, has been named Senior Vice President and Chief Information and Digital Officer (CIDO).
- PR Newswire
Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology, today announced a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases.
